MarketsandMarkets Presents
Tumor Ablation Market worth 580.1 Million USD by 2021
http://www.marketsandmarkets.com/Market-Reports/tumor-ablation-market142550258.html
The report "Tumor Ablation Market by Technology (Radiofrequency, Microwave, Cryoablation, IRE, Ultrasound, Laser), Mode of Treatment (Surgical, Laparoscopic, Percutaneous), Application (Liver, Lung, Kidney, Bone Metastasis, Prostate, Breast) Global Forecast 2021" , analyzes and studies the major market drivers, restraints, opportunities, and challenges in North America, Europe, Asia-Pacific, and the Rest of the World (RoW). Browse: 72 market data tables 86 figures 183 pages And in-depth TOC on ÍžTumor Ablation MarketÍ&#x; Download The PDF Brochure@ http://www.marketsandmarkets.com/pdfdownload.asp?id=142550258 This report studies the tumor ablation market over the forecast period of 2016 to 2021. The market is expected to reach USD 580.1 Million by 2021, at a CAGR of 12.5% during 2016 to 2021. http://www.marketsandmarkets.com/Market-Reports/tumor-ablation-market-142550258.html
On the basis of technology, the global tumor ablation market is divided into four major categories, namely, radiofrequency ablation, microwave ablation, cryoablation, and others (includes electrical, laser/light, and ultrasound). Based on the mode of treatment, the tumor ablation market is segmented into surgical mode, laparoscopic mode, and percutaneous mode.
Talk To Our Research Experts@ http://www.marketsandmarkets.com/speaktoanalyst.asp?id=142550258 On the basis of application of tumor ablation, the market is categorized into liver cancer,
lung cancer, kidney/renal cancer, bone metastasis, and others (includes tumor ablation for the treatment of prostate, breast, colorectal, thyroid, pancreas, neuroendocrine, head, neck, and lumbar-vertebra cancer).
http://www.marketsandmarkets.com/Market-Reports/tumor-ablation-market-142550258.html
In 2016, the radiofrequency ablation segment is expected to command the largest share in the global tumor ablation market, which can primarily be attributed to its ease of treatment (as compared to open surgical procedures), proven clinical efficacy and safety profile, and ongoing developments & commercialization of technologically advanced radiofrequency tumor ablation systems.
However, during 2016-2021, the microwave ablation segment is expected to form the fastest-growing technology segment due to its additional therapeutic benefits such as faster heat-generation (which reduces the susceptibility to damage to surrounding organs
and gives opportunity to ablate larger tumors), lower heat-sink effect (that results in destruction of surrounding healthy tissue), and better safety & efficacy profile.
http://www.marketsandmarkets.com/Market-Reports/tumor-ablation-market-142550258.html
North America is expected to form the largest regional segment in the global tumor ablation market in 2016, followed by Europe. The Asia-Pacific market is expected to form the fastest-growing region, with a double-digit CAGR during 2016-2021. A number of factors including increasing prevalence of cancer coupled with rising geriatric population, increasing medical tourism due to lower treatment costs, growing market penetration of major players, and evolving regulatory scenario are stimulating the growth of the tumor
ablation market in the Asia-Pacific region.
As of 2015, Angiodynamics, Inc. (U.S.), Boston Scientific Corporation (U.S.), Galil Medical,
Inc. (U.S.), EDAP TMS S.A. (France), Healthtronics, Inc. (U.S.), Medtronic, Plc (U.S.), Mermaid Medical, Inc. (Denmark), Mesonix, Inc. (U.S.), Neuwave Medical, Inc. (U.S.), and Sonacare Medical, LLC (U.S.) are key players operating in the global tumor ablation market.
http://www.marketsandmarkets.com/Market-Reports/tumor-ablation-market-142550258.html
About MarketsandMarkets™ Marketsa dMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide co pa ies’ revenues. Currently servicing 5000 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach Marketsa dMarkets™ for their painpoints around revenues decisions. Our 850 fulltime analyst and SMEs at Marketsa dMarkets™ are tracking global high growth markets following the "Growth Engagement Model – GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. Marketsa dMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. Marketsa dMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve. Marketsa dMarkets’s flagship competitive intelligence and market research platform, "RT" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.
http://www.marketsandmarkets.com/Market-Reports/tumor-ablation-market-142550258.html
Contact Us Mr. Rohan MarketsandMarkets™ 701 Pike Street Suite 2175, Seattle, WA 98101, United States Tel: 1-888-600-6441 Email: sales@marketsandmarkets.com MarketsandMarkets Blog http://www.marketsandmarkets.com http://twitter.com/marketsmarkets http://www.linkedin.com/company/marketsandmarkets